Aprea Therapeutics Management
Management criteria checks 4/4
Aprea Therapeutics' CEO is Oren Gilad, appointed in Jan 2011, has a tenure of 14.33 years. total yearly compensation is $760.09K, comprised of 75.3% salary and 24.7% bonuses, including company stock and options. directly owns 6.07% of the company’s shares, worth $619.73K. The average tenure of the management team and the board of directors is 3.7 years and 4 years respectively.
Key information
Oren Gilad
Chief executive officer
US$760.1k
Total compensation
| CEO salary percentage | 75.25% |
| CEO tenure | 14.3yrs |
| CEO ownership | 6.1% |
| Management average tenure | 3.7yrs |
| Board average tenure | 4yrs |
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Mar 31 2025 | n/a | n/a | -US$14m |
| Dec 31 2024 | US$760k | US$572k | -US$13m |
| Sep 30 2024 | n/a | n/a | -US$14m |
| Jun 30 2024 | n/a | n/a | -US$13m |
| Mar 31 2024 | n/a | n/a | -US$13m |
| Dec 31 2023 | US$877k | US$550k | -US$14m |
| Sep 30 2023 | n/a | n/a | -US$13m |
| Jun 30 2023 | n/a | n/a | -US$14m |
| Mar 31 2023 | n/a | n/a | -US$109m |
| Dec 31 2022 | US$753k | US$324k | -US$113m |
Compensation vs Market: Oren's total compensation ($USD760.09K) is about average for companies of similar size in the US market ($USD655.68K).
Compensation vs Earnings: Oren's compensation has been consistent with company performance over the past year.
CEO
Oren Gilad (56 yo)
14.3yrs
Tenure
US$760,091
Compensation
Dr. Oren Gilad, Ph.D. is Co-Founder of Aprea Therapeutics, Inc (formerly known as Atrin Pharmaceuticals LLC) since 2011 and serves as its Chief Executive Officer since July 2022. Dr. Gilad serves as Presid...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder | 14.3yrs | US$760.09k | 6.07% $ 619.7k | |
| Senior VP | 2.3yrs | US$536.65k | 0.23% $ 23.5k | |
| Senior VP & Chief Scientific Officer | 10.6yrs | no data | no data | |
| Senior Vice President of Corporate Development & Strategy | 1.5yrs | no data | no data | |
| Head of Pharmacology Development | 7.3yrs | no data | no data | |
| Chief Business Advisor | 3yrs | no data | no data | |
| Controller | 3.7yrs | no data | no data |
3.7yrs
Average Tenure
60yo
Average Age
Experienced Management: APRE's management team is considered experienced (3.7 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder | 3yrs | US$760.09k | 6.07% $ 619.7k | |
| Independent Director | 10.3yrs | US$75.93k | 0.80% $ 81.3k | |
| Independent Director | 5.8yrs | US$75.43k | 0.15% $ 15.1k | |
| Independent Director | 3yrs | US$70.43k | 0.32% $ 32.5k | |
| Independent Director | 3yrs | US$62.43k | 4.25% $ 433.8k | |
| Scientific & Clinical Advisory Board Member | 6.3yrs | no data | no data | |
| Independent Chairperson of the Board | 4.9yrs | US$97.43k | 0.019% $ 1.9k | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Independent Director | 3yrs | US$71.93k | 0.015% $ 1.5k | |
| Scientific & Clinical Advisory Board Member | no data | no data | no data | |
| Scientific & Clinical Advisory Board | no data | no data | no data | |
| Scientific & Clinical Advisory Board Member | no data | no data | no data |
4.0yrs
Average Tenure
64yo
Average Age
Experienced Board: APRE's board of directors are considered experienced (4 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/19 19:49 |
| End of Day Share Price | 2025/05/16 00:00 |
| Earnings | 2025/03/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Aprea Therapeutics, Inc. is covered by 4 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Esther Lannie Hong | Berenberg |
| Joseph Pantginis | H.C. Wainwright & Co. |
| Jason McCarthy | Maxim Group |